Tina Cascone
Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated.
Overview
Tina Cascone was principal investigator of CheckMate 77T, which showed neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab improves event-free survival in resectable NSCLC, and led the NEOSTAR window trials that defined pathological response endpoints. Her laboratory studies the immune correlates of response to neoadjuvant therapy.
Pages like this
not linked directly; found by shared links- PersonJonathan Spicer
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Nivolumab, Non-small-cell lung cancer and the tags lung, neoadjuvant.
- PersonPatrick M. Forde
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Nivolumab, PD-1.
- PersonMartin Reck
Shares PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
- PersonJennifer A. Wargo
Shares MD Anderson Cancer Center, Ipilimumab, Nivolumab, Immune checkpoint inhibitors and the tag neoadjuvant.
- PersonScott J. Antonia
Shares Nivolumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
- PersonTimothy F. Cloughesy
Shares PD-1, Immune checkpoint inhibitors and the tags neoadjuvant, immunotherapy.
- PersonPaul Baas
Shares Ipilimumab, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonRoy S. Herbst
Shares PD-1, Non-small-cell lung cancer and the tags lung, immunotherapy.